Ponatinib Hydrochloride is the hydrochloride salt form of ponatinib, a medication mainly used to treat certain blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors, Tyrosine Kinase Inhibitors and VEGF inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Iclusig, Ponatinib (HCl salt) and Ponatinib (hydrochloride). Its PubChem CID is 46908927.
Ponatinib hydrochloride
| CAS No | 1114544-31-8 |
|---|---|
| Molecular Formula | C29H28ClF3N6O |
| Molecular Weight | 569.0 g/mol |
| Synonyms | 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ponatinib Hydrochloride is the hydrochloride salt form of ponatinib, a medication mainly used to treat certain blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
The listed CAS number is 1114544-31-8.
The listed molecular formula is C29H28ClF3N6O.
The listed molecular weight is 569.0 g/mol.
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;hydrochloride.
The source lists Iclusig, Ponatinib (HCl salt) and Ponatinib (hydrochloride).